UBT251 Injection 4.0 mg (ID 1.0 mg) and UBT251 Injection Placebo

DRUG2 trials

Sponsors

The United Bio-Technology (Hengqin) Co., Ltd.

Conditions

Obesity &Amp; OverweightType 2 Diabetes Mellitus (T2DM)

Phase 2

UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study

CompletedNCT07163624

The United Bio-Technology (Hengqin) Co., Ltd.Type 2 Diabetes Mellitus (T2DM)

Start: 2025-03-22End: 2025-12-30Updated: 2026-05-07

UBT251 Injection Phase II Study (Overweight or Obesity)

CompletedNCT07177469

The United Bio-Technology (Hengqin) Co., Ltd.Obesity &Amp; Overweight

Start: 2025-03-14End: 2025-11-19Updated: 2026-05-07

Related Papers

3090-LB: UBT251, a Triple Hormone Receptor Agonist in Adults with Overweight or Obesity: A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 2 Trial

Diabetes2026-06-05